85-58-5

Usage

Uses

Used in Scientific Research:
BENZOPHENONE-2,4'-DICARBOXYLIC ACID is used as a research chemical for studying its properties and potential applications in various fields.
Used in Resin Manufacturing:
BENZOPHENONE-2,4'-DICARBOXYLIC ACID is used as a chemical intermediate for the production of different types of resins, contributing to their structural and functional characteristics.
Used in Pharmaceutical Industry:
BENZOPHENONE-2,4'-DICARBOXYLIC ACID is used as a building block in the synthesis of pharmaceutical compounds, potentially leading to the development of new drugs.
Used in Polymer Production:
BENZOPHENONE-2,4'-DICARBOXYLIC ACID is used as a monomer or a component in the production of polymers, which can be utilized in various applications such as plastics, coatings, and adhesives.

Upstream product

• 1140-16-5 (2-methylphenyl)(4-methylphenyl)methanone 
• 85-55-2 2-(4-toluoyl)benzoic acid 
• 65414-25-7 4-(2-methylbenzoyl)benzoic acid 
• 82101-39-1 4-(p-tolyl)-1-tetralone 
• 19772-67-9 2-Chlor-3-(4-tolyl)-indenon-⁽¹⁾ 
• 42797-18-2 2-(4-phenylbenzoyl)benzoic acid 
• 64-19-7 acetic acid 
• 932-31-0 ortho-tolylmagnesium bromide 
• 100-20-9 terephthaloyl chloride 

Downstream Products

• 6268-08-2 2,4'-methanediyl-di-benzoic acid 
• 152567-94-7 4-(4-Oxo-3,4-dihydro-phthalazin-1-yl)-benzoic acid 
• 117-78-2 anthraquinone-2-carboxylic acid 
• 100-21-0 terephthalic acid 
• 65-85-0 benzoic acid 
• 1401685-99-1 [Zn(2-(4-pyridyl)benzimidazole)(benzophenone-2,4'-dicarboxylate)]n 
• 152567-72-1 4-[3-(2-Imidazol-1-yl-ethyl)-4-oxo-3,4-dihydro-phthalazin-1-yl]-benzoic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors

Many clinical trials using combinations of platinum drugs and PARP-1 inhibitors (PARPi) have been carried out, with the hope that such combinations will lead to enhanced therapeutic outcomes against tumors. Herein, we obtained seven potential PARPi with structural diversity and then conjugated them with cisplatin-based platinum(IV) complexes. Both the synthesized PARPi ligands and PARPi-Pt conjugates [PARPi-Pt(IV)] show inhibitory effects against PARP-1's catalytic activity. The PARPi-Pt(IV) conjugates are cytotoxic in a panel of human cancer cell lines, and the leading ones display the ability to overcome cisplatin resistance. A mechanistic investigation reveals that the representative PARPi-Pt(IV) conjugates efficiently enter cells, bind to genomic DNA, disturb cell cycle distribution, and induce apoptotic cell death in both cisplatin-sensitive and-resistant cells. Our study provides a strategy to improve the cytotoxicity of platinum(IV)-based anticancer complexes and overcome cisplatin resistance by using a small-molecule anticancer complex that simultaneously damages DNA and inhibits PARP.